Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Molecular Profile (CAS 2381089-83-2) Storage, Handling, and Reconstitution of Retatrutide Store lyophilized powder at -20 C, desiccated, protected from light
Active secretion begins at the blastocyst stage, enabling hCG detection in the maternal circulation approximately 10 days after fertilisation, with the highest values reached between the 10th and 11th week of pregnancy before declining through the remainder of the first trimester
Practice aseptic technique at every injection: clean vial stopper and skin with separate alcohol swabs, allow to air-dry completely